OBJECTIVE: To determine whether ischaemia grade (GI) on the presenting ECG and duration of symptoms can identify subgroups of patients who would derive more benefit than the general population of patients with ST segment elevation acute myocardium infarction (STEMI) from primarypercutaneous coronary intervention (pPCI) over thrombolytic treatment (TT) in reducing mortality or reinfarction. METHODS:1319 DANAMI-2 (Danish trial in Acute Myocardial Infarction-2) patients were classified as having grade 2 ischaemia (GI2; ST segment elevation without terminal QRS distortion) or grade 3 ischaemia (GI3; ST segment elevation with terminal QRS distortion in > or = 2 adjacent leads), and were divided into early and late groups split by the median time (3 h) from symptom onset to treatment. Outcomes were 30-day mortality and reinfarction. RESULTS:Mortality was significantly higher for GI3 than for GI2 (9.7% v 4.8%, p < 0.001) and doubled for patients presenting late (GI2: 6.0% v 3.3%, p = 0.01; GI3: 12.5% v 4.7%, p = 0.05). Overall mortality did not differ significantly between pPCI and TT; however, a 5.5% absolute mortality reduction was seen in GI3 treated early with pPCI (1.4% v 6.9%, p = 0.10). Reinfarction rate was particularly high among GI3 patients presenting late and treated with TT (12.2%). pPCI in such patients significantly reduced the rate of reinfarction (0%, p < 0.001). Logistic regression analysis showed that age (odds ratio (OR) 1.09, 95% confidence interval (CI) 1.06 to 1.12, p < 0.001), prior angina (OR 2.56, 95% CI 1.44 to 4.54, p = 0.001), heart rate (OR 1.03, 95% CI 1.01 to 1.04, p = 0.001) and GI3 (OR 1.91, 95% CI 1.06 to 3.44, p = 0.031) were independently associated with mortality, whereas the sum of ST segment elevation was not. CONCLUSIONS: GI3 is an independent predictor of mortality among patients with STEMI. Mortality increased significantly with symptom duration in both GI2 and GI3. pPCI may be especially beneficial for patients with GI3 presenting early, whereas patients with GI3 presenting late and treated withTT are at particular risk of reinfarction.
RCT Entities:
OBJECTIVE: To determine whether ischaemia grade (GI) on the presenting ECG and duration of symptoms can identify subgroups of patients who would derive more benefit than the general population of patients with ST segment elevation acute myocardium infarction (STEMI) from primary percutaneous coronary intervention (pPCI) over thrombolytic treatment (TT) in reducing mortality or reinfarction. METHODS: 1319 DANAMI-2 (Danish trial in Acute Myocardial Infarction-2) patients were classified as having grade 2 ischaemia (GI2; ST segment elevation without terminal QRS distortion) or grade 3 ischaemia (GI3; ST segment elevation with terminal QRS distortion in > or = 2 adjacent leads), and were divided into early and late groups split by the median time (3 h) from symptom onset to treatment. Outcomes were 30-day mortality and reinfarction. RESULTS: Mortality was significantly higher for GI3 than for GI2 (9.7% v 4.8%, p < 0.001) and doubled for patients presenting late (GI2: 6.0% v 3.3%, p = 0.01; GI3: 12.5% v 4.7%, p = 0.05). Overall mortality did not differ significantly between pPCI and TT; however, a 5.5% absolute mortality reduction was seen in GI3 treated early with pPCI (1.4% v 6.9%, p = 0.10). Reinfarction rate was particularly high among GI3 patients presenting late and treated with TT (12.2%). pPCI in such patients significantly reduced the rate of reinfarction (0%, p < 0.001). Logistic regression analysis showed that age (odds ratio (OR) 1.09, 95% confidence interval (CI) 1.06 to 1.12, p < 0.001), prior angina (OR 2.56, 95% CI 1.44 to 4.54, p = 0.001), heart rate (OR 1.03, 95% CI 1.01 to 1.04, p = 0.001) and GI3 (OR 1.91, 95% CI 1.06 to 3.44, p = 0.031) were independently associated with mortality, whereas the sum of ST segment elevation was not. CONCLUSIONS: GI3 is an independent predictor of mortality among patients with STEMI. Mortality increased significantly with symptom duration in both GI2 and GI3. pPCI may be especially beneficial for patients with GI3 presenting early, whereas patients with GI3 presenting late and treated with TT are at particular risk of reinfarction.
Authors: F Zijlstra; A Patel; M Jones; C L Grines; S Ellis; E Garcia; L Grinfeld; R J Gibbons; E E Ribeiro; F Ribichini; C Granger; F Akhras; W D Weaver; R J Simes Journal: Eur Heart J Date: 2002-04 Impact factor: 29.983
Authors: Therese Billgren; Charles Maynard; Timothy F Christian; Mohmmad A Rahman; Mahammad Saeed; Stephen C Hammill; Galen S Wagner; Yochai Birnbaum Journal: J Electrocardiol Date: 2005-07 Impact factor: 1.438
Authors: Francisco Fernandez-Avilés; Joaquín J Alonso; Alfonso Castro-Beiras; Nicolás Vázquez; Jesús Blanco; Juan Alonso-Briales; Juan López-Mesa; Felipe Fernández-Vazquez; Isabel Calvo; Luis Martínez-Elbal; José A San Román; Benigo Ramos Journal: Lancet Date: 2004 Sep 18-24 Impact factor: 79.321
Authors: Elliott M. Antman; Daniel T. Anbe; Paul Wayne Armstrong; Eric R. Bates; Lee A. Green; Mary Hand; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; Gervasio A. Lamas; Charles J. Mullany; Joseph P. Ornato; David L. Pearle; Michael A. Sloan; Sidney C. Smith; Joseph S. Alpert; Jeffrey L. Anderson; David P. Faxon; Valentin Fuster; Raymond J. Gibbons; Gabriel Gregoratos; Jonathan L. Halperin; Loren F. Hiratzka; Sharon Ann Hunt; Alice K. Jacobs; Joseph P. Ornato Journal: J Am Coll Cardiol Date: 2004-08-04 Impact factor: 24.094
Authors: Therese Billgren; Yochai Birnbaum; Elena B Sgarbossa; Maria Sejersten; Norma E Hill; Henrik Engblom; Charles Maynard; Olle Pahlm; Galen S Wagner Journal: J Electrocardiol Date: 2004-07 Impact factor: 1.438
Authors: Yochai Birnbaum; James Michael Wilson; Miquel Fiol; Antonio Bayés de Luna; Markku Eskola; Kjell Nikus Journal: Ann Noninvasive Electrocardiol Date: 2013-12-30 Impact factor: 1.468
Authors: Turgay Celik; U Cagdas Yuksel; Atila Iyisoy; Selim Kilic; Ejder Kardesoglu; Baris Bugan; Ersoy Isik Journal: Ann Noninvasive Electrocardiol Date: 2008-07 Impact factor: 1.468
Authors: Karl Heinrich Scholz; Thomas Meyer; Björn Lengenfelder; Christian Vahlhaus; Jörn Tongers; Steffen Schnupp; Rainer Burckhard; Nicolas von Beckerath; Hans-Martin Grusnick; Andreas Jeron; Klaus Dieter Winter; Sebastian K G Maier; Michael Danner; Jürgen Vom Dahl; Stefan Neef; Stefan Stefanow; Tim Friede Journal: Open Heart Date: 2021-05